Business Context and Reporting Period
This Form 8-K, filed on November 3, 2014, by Platform Specialty Products Corporation (not Element Solutions Inc), reports the completion of a major acquisition and associated financing activities. The primary event is the acquisition of Chemtura AgroSolutions ("CAS") from Chemtura Corporation.
Key Financial Metrics and Transaction Details
- Acquisition Price: Approximately $1.00 billion total consideration.
- Payment Structure: $950 million in cash (subject to adjustments), 2,000,000 shares of Platform common stock, and assumption of certain liabilities.
- Financing - New Term Loans: $130 million in new Tranche B term loans.
- Financing - Euro Loans: €205 million in Euro Tranche Term Loans borrowed by a new subsidiary (MASBV) and a U.S. co-borrower (NAIP).
- Financing - Revolving Credit: U.S. Dollar and multicurrency revolving facilities increased by $62.5 million each to $87.5 million; $60 million and €55 million were drawn under these facilities.
- Debt Maturity: Euro Tranche Term Loans mature on June 7, 2020.
Material Changes
The filing details significant changes to the company's capital structure and asset base effective November 3, 2014:
- Asset Expansion: Addition of the CAS agrochemicals business to Platform's portfolio.
- Debt Restructuring: Execution of the Second Amended and Restated Credit Agreement, adding new borrowers (MASBV and NAIP) and increasing total debt capacity.
- Covenant Flexibility: Amendments provided additional flexibility regarding limiting covenants, including increased dollar baskets.
Outlook, Risks, and Unusual Items
The transaction was financed through a combination of new borrowings under the amended credit agreement and existing cash on hand. The filing incorporates pro forma financial information giving effect to the CAS Acquisition, the previously announced Arysta LifeScience Limited acquisition, and the MacDermid Holdings acquisition. No specific forward-looking guidance or risk factors beyond the standard incorporation of the purchase agreement and credit terms are detailed in the text of this specific report.
Investor Verification Checklist
- Verify the final purchase price adjustments for the $950 million cash component of the CAS Acquisition.
- Review the full text of the Second Amended and Restated Credit Agreement (Exhibit 10.1) for specific interest rate margins and covenant details.
- Examine the unaudited pro forma financial statements (Exhibit 99.5) to assess the combined entity's leverage and liquidity post-acquisition.
- Confirm the integration timeline and expected synergies for the CAS business as outlined in the press release (Exhibit 99.1).